

## Index

### a

- AC133 179  
 acquisition of stem cell 57  
 $\beta$ -actin promoter 134  
 acute ischemia 151  
 acute lymphoid leukemia (ALL) 222, 240  
 acute myeloid leukemia (AML) 222 ff., 239  
 ADA-SCID gene therapy clinical trial 110  
 adenosine deaminase (ADA) 110  
 adhesion 184, 234  
   – cell-cell 63  
   – cell-ECM 63  
   – molecule 62  
 adipocyte 77, 150  
 adipose tissue 94, 233  
 adoptive immunotherapy 221 ff.  
 adult stem cell (ASC) 6 ff., 237  
   – plasticity potential 6 ff.  
   – trans-differentiation 6 ff.  
 alkaline phosphatase (ALP)  
   – bone-specific 77  
 ALL, *see* acute lymphoid leukemia  
 allogeneic stem cell transplantation  
   (allo-SCT) 221, 234, 247 ff.  
 alloreactivity 237  
 AMD-3100 63 f.  
 AML, *see* acute myeloid leukemia  
 amniotic fluid 94  
 angiogenesis 158 f., 185, 202  
 animal model 109 f., 147 ff.  
   – clonality analysis 109 ff.  
   – fetal sheep 80, 123 ff.  
   – mouse 109, 112, 152  
   – non-human primate 110  
   – non-injury model 121  
   – potential of MAPC 147 ff.  
 antibody 221 ff.  
   – bispecific 227  
 antigen expression 92  
   – hematopoietic 92  
 antithymocyte globulin 222  
 antitumor  
   – activity 29  
   – agent 158  
 Ara-C (cytarabine) 226  
 Argonaute protein 46  
 arterial and venous oxygen content (AVDO<sub>2</sub>)  
   198  
 arteriogenesis 150, 203  
 arylsulfatase A 239  
 ASC, *see* adult stem cell  
 asymmetric cell division 12, 28  
 autoimmune disorder 234  
 autologous stem cell transplantation 249  
 5-azacytidine (5azaD) 29 ff., 206  
 5-aza-2'-desoxycytidine 29

### b

- B-cell 151, 247 ff.  
   – lymphoma 247  
 basic fibroblast growth factor (bFGF) 134,  
   158  
 Berashi cell 73  
 blastocyst 133 ff.  
   – transfer 135  
 blood cell 6  
 blood stem cell  
   – mobilization 57 f.  
 bone 77 ff.  
 bone marrow (BM) 61, 73 ff., 122, 147, 159,  
   202 ff.  
   – bone marrow-derived mononuclear cell  
     (BMC) 189, 209  
   – mesenchymal stem cell 83, 128, 157  
   – stem cell 210  
   – transplantants 7  
   – transplantation 7, 122  
 bone morphogenetic protein 34, 238  
 bypass grafting 197 ff.

**c**

- C3aR antagonist 66
  - CABG, *see* coronary artery bypass grafting
  - CAD, *see* coronary artery disease
  - CAFC, *see* cobblestone area-forming cell
  - cancer, *see* tumor
  - cardiac regeneration 179 ff.
  - cardiomyocyte 151, 205 f.
  - cardiomyopathy 191
  - cartilage 77 ff.
  - CD14<sup>+</sup> mononuclear cell 180
  - CD26 62
  - CD34 11, 28 ff., 210, 228, 234
    - CD34<sup>+</sup> cell 100 ff., 128, 179
    - CD34<sup>+</sup> cell differentiation 28 ff.
    - CD34<sup>+</sup> cell mobilization 63
    - CD34<sup>+</sup> stem/progenitor cell 60
  - CD38 11
  - CD44
  - CD45<sup>-</sup> 142, 234
  - CD45<sup>+</sup> 102
  - CD133 11, 179, 210
  - cell culture
    - trans-differentiated 9
  - cell fusion 137 ff., 205
  - cell membrane raft formation 62
  - cell plating density 94
  - cell therapy 200 ff., 247 ff.
  - cellular microenvironment 15
  - central nervous system (CNS) 12
  - CFC, *see* colony-forming cell
  - chemoattractant 142, 181
  - chemokine 142, 186
  - chemotaxis 186
  - chimerism 135 ff., 229
  - chondroblast 150
  - chromatin modification 9
    - chromatin-modifying agent 27 ff.
  - chromosome instability 36
  - chronic ischemia 151
  - chronic lymphocytic leukemia (CLL) 227, 247 ff.
  - chronic myelogenous leukemia (CML) 221 ff.
  - circulating system 202
  - clinical studies 18
  - clinical scale production 91 ff.
  - coating 168
  - cobblestone area-forming cell (CAFC) 31
  - colony-forming cell (CFC) 33
  - colony-forming unit fibroblast (CFU-Fs) 91
  - concanavalin A 235
  - connexin 43 (Cx43) 207
  - cord blood (CB) 33, 61, 73 ff., 93
    - cryoconserved 76
    - mesenchymal stem cell 85
    - umbilical cord blood 73 ff., 93, 126
  - coronary artery bypass grafting (CABG) 197 ff.
    - off-pump 201
    - surgery 199 ff., 214
  - coronary artery disease (CAD) 197 f.
  - Creutzfeld-Jakob disease 95
  - CTCE0021 65
  - CTCE0214 65
  - culture condition 180
    - *ex-vivo* 150
    - *in-vitro* 142
  - CXCL2Δ4 66
  - CXCR4 57 ff.
    - pathway 58
  - cytarabine (Ara-C) 226
  - cytokine 221 ff.
    - delivery 165
    - production 82 f.
  - cytomegalovirus (CMV) 73
    - enhancer 134
  - cytotoxicity 29 ff.
  - cytotoxic T-lymphocyte (CTL) 235
- d**
- decitabine 29
  - delivery
    - coating 168
    - MSC-based 167
    - therapeutic gene 165
    - vehicle 157 ff.
  - Delta 24 virus 169
  - desmoplastic reaction 164
  - development potential 133 ff.
  - dextran sulphate (DEX) 61
  - Dicer 46 f.
  - differentiation 7 ff., 150 f., 183, 206 ff., 233 f.
    - dopaminergic 150
    - multilineage 7
    - multipotent 147
    - pluripotent 147
    - potential 35, 126, 150 ff.
    - stage 137
    - trans-differentiation 6 ff.
  - division 12
    - asymmetric 12
    - symmetric 12
  - DNA (cytosine-5)-methyltransferase (*dnmt1*) 16, 29
  - Dolly 3
  - donor lymphocyte infusion (DLI) 249
  - donor lymphocyte transfusion (DLT) 221 f.
  - dopaminergic differentiation 150
  - Drosha 46

**e**

E-selectin 185  
 ECM, *see* extracellular matrix  
 ectodermal derivation 121  
 embryo  
 – murine 141  
 – permanent embryo 5  
 embryogenesis 121  
 embryonal carcinoma (EC) cell 143  
 embryonic antigen 148  
 – stage-specific (SSEA) 148  
 embryonic hematopoietic tissue 142  
 embryonic progenitor cell homing 185  
 embryonic state 143  
 – pluripotent 143  
 embryonic stem cell (ESC) 3 ff.  
 – differentiation 14  
 – pluripotency 28  
 endoderm 122  
 endothelial cell 158  
 endothelial differentiation 180  
 endothelial growth factor (EGF) 134  
 endothelial progenitor cell (EPC) 151, 179 ff.  
 – circulating bone marrow-derived (CEPC) 179  
 – heterogeneity 180  
 endothelium 151  
 enzyme replacement therapy 112  
 epigenetic alteration 133 ff., 206  
 epigenetic mechanism 28  
 Epstein-Barr virus (EBV) 73  
 erythroid-like cell 134  
 erythroleukemia 143  
 ESC, *see* embryonic stem cell  
 ethics 143  
 expansion 33 ff.  
 – *ex-vivo* 33, 182  
 – malignant expansion 112  
 Exportin 46  
 extracellular matrix (ECM) 63, 158 ff.

**f**

FDCEmix cell 142  
 fetal sheep  
 – model 123 ff.  
 – preimmune 81  
 – xenograft model 80  
 fibroblast 158  
 Flt3 ligand (FL) 60  
 fludarabine 252  
 follicular lymphoma (FL) 253  
 fumarylacetoacetate hydrolase (FAH) 152  
 fusion 183

**g**

G-CSF, *see* granulocyte colony-stimulating-factor  
 G6PD, *see* glucose-6-phosphate dehydrogenase  
 GAG, *see* glycosaminoglycan  
 ganglion mother cell (GMC) 12  
 gap junction protein 207  
 gene deletion 143  
 gene expression 34  
 – dynamics 28  
 gene therapy 109  
 – clinical trial 110 f.  
 – clonality analysis 109 ff.  
 genetic targeting 157  
 genotype 14  
 germ layer 121, 149 f.  
 germline stem cell (GSC) 14  
 glial fibrillary acidic protein (GFAP) 80  
 globulin 222  
 – antithymocyte 222  
 glucose-6-phosphate dehydrogenase (G6PD) 108  
 glycosaminoglycan (GAG) 151  
 GMC, *see* ganglion mother cell  
 graft versus host disease (GVDH) 63, 221 f., 249  
 graft versus leukemia (GVL) effect 224, 249  
 granulocyte colony-stimulating-factor (G-CSF) 57 ff.  
 GROβT 66  
 growth factor 142

**h**

heart failure 190  
 hemangioblast 202  
 hematopoiesis 36, 82 ff.  
 – *in vivo* 80  
 hematopoietic cell 151  
 hematopoietic chimerism 138, 247  
 hematopoietic engraftment 126  
 hematopoietic stem cell (HSC) 6 ff., 27 ff., 107 ff., 133 f.  
 – acquisition 57 ff.  
 – asymmetric cell division 28  
 – 5azaD/TSA treatment 30 ff.  
 – chromatin-modifying agent 27 ff.  
 – clonal activity 107 ff.  
 – differentiation 234  
 – *ex-vivo* expansion 33  
 – expression profile 14  
 – fast-dividing fraction (FDF) 14  
 – fetal sheep 124  
 – genetic marker 107

- genotype 14
  - human cord blood-derived 138
  - malignant expansion 112
  - marked HSC 109 ff.
  - myogenic potential 216
  - slow-dividing fraction (SDF) 14
  - symmetric cell division 35
  - transplantation 163
  - hematopoietic system 73
  - hepatic cell 81
  - hepatocyte 126, 133, 151
    - hepatocyte-like cell 152
  - hereditary tyrosinemia type I (HT1) 152
  - heterogeneity 180
  - histone acetylation 28
  - histone deacetylase (HDAC) 29
    - HDAC inhibitor 30 ff.
  - HLA, *see* human leukocyte antigen
  - HMG-CoA reductase 60
  - homeostasis 157
  - homing 61 f., 162, 184
    - mechanism 184
  - HoxB4 33 ff.
  - HSC, *see* hematopoietic stem cell
  - human gene therapy 109 ff.
    - clonality analysis 109 ff.
  - human leukocyte antigen (HLA) 228, 234
    - HLA-DR 11
    - HLA-haploidentical transplantation 228
    - HLA-identical related donor (ID-SCT) 251
    - HLA-identical sibling transplants 240, 252 ff.
    - HLA-matched unrelated donor (UD-SCT) 256
  - human umbilical cord perivascular cell (HUCPV) 85
  - Hurler's disease 239
  - hyaluronic acid (HA) 60
  - hypomethylation 29
  - hypoxia-inducible factor-1 (HIF-1) 186
- i**
- $\alpha$ -L-iduronidase 239
  - IFN, *see* interferon
  - IL, *see* interleukin
  - immune escape 233 f.
  - immune system 6 ff., 150 f.
  - immunosuppression 233 ff.
  - immunotherapy 247 ff.
    - adoptive 221 ff.
  - implantable cardioverter defibrillator (ICD) 207
  - indoleamine 2,3-dioxygenase (IDO) 238
  - information
    - cell-autonomous 12
    - intrinsic 12
  - initiating cell
    - long-term (LTC-IC) 11
    - myeloid-lymphoid initiating cell (ML-IC) 11
  - inner cell mass 4
  - $\beta_2$ -integrin 184
  - interferon-alpha (IFN- $\alpha$ ) 225
  - interferon-beta (IFN- $\beta$ ) 165
  - interferon-gamma (IFN- $\gamma$ ) 234 ff.
  - interleukin (IL) 59, 186, 225
    - IL-2 receptor gamma common chain ( $\gamma$ c) 111
  - international bone marrow transplant registry (IBMTR) 253
  - invasion 186
  - ischemia 151, 198
    - myocardial 198
  - ischemic cardiomyopathy 191
  - ischemic heart failure 190
  - ischemic myocardium 189
- j**
- JAK-STAT signalling cascade 14
  - junction sequences
    - proviral-genomic 108
- k**
- kinase inhibitor 143
- l**
- left ventricular (LV) function 200
  - leukemia 8, 221 ff.
    - acute lymphoid leukemia (ALL) 222
    - acute myeloid leukemia (AML) 139 ff., 222 ff.
    - chronic lymphocytic leukemia (CLL) 227
    - chronic myelogenous leukemia (CML) 221 ff.
    - erythroleukemia 143
  - leukemic cell 138
  - lineage commitment 11
  - linear amplification-mediated PCR (LAM-PCR) 109
  - LMO2 insertion 112
  - long-term initiating cell (LTC-IC) 11
  - LV, *see* left ventricular function
  - lymphocyte 221
    - donor lymphocyte infusion (DLI) 249
    - donor lymphocyte transfusion (DLT) 221 f.

- lymphoma 222, 247 ff.
  - lymphoplasmacytic lymphoma 255
- m**
- major histocompatibility complex (MHC) 164, 234
- MAPC, *see* multipotent adult progenitor cell
- matrix-degrading protease 162
- MCP-1, *see* monocyte chemoattractant protein-1
- mesenchymal lineage 150, 210
- mesenchymal stem cell (MSC) 16 ff., 73 ff., 122 ff., 157 ff., 233
  - adult 237
  - bone marrow (BMSC) 190
  - clinical-scale production 91 ff.
  - differentiation 128
  - fetal 237
  - homing 162
  - immune escape 233
  - immunosuppression 235
  - lineage 77
  - MSC-based cellular mini-pump 158
  - precursor cell 81
  - quality assurance 99
  - quality control 99
  - starting material 92
  - stroma cell-derived 206
- mesenchymal tissue 163
- mesodermal cell 152
- mesodermal derivation 122
- metachromatic leukodystrophy (MLD) 239
- metastase 157
- methyl- $\beta$ -cyclodextrin 62
- micro RNA (miRNA) 43 ff.
  - biogenesis 44
  - potential function mode 48 f.
- micro ribonucleoprotein (miRNP) 46
- microenvironment 15, 142 f.
  - influence 126
  - nonmalignant 158
  - tumor 161 ff.
- migration 186
- mini-pump 165
  - MSC-based cellular mini-pump 158
- mitogen 235
- mixed lymphocyte culture (MLC) 235
- MLD, *see* metachromatic leukodystrophy
- MLV, *see* murine leukemia virus
- mobilization 62 f.
- mobilized peripheral blood (mPB) 126
- model
  - animal model 109 f., 147 ff.
  - animal non-injury model 121
    - fumarylacetoacetate hydrolase (FAH) 152
    - fetal sheep 80, 123 ff.
    - *in-vivo* 123
    - LMO2 transgenic mouse model 112
    - mouse model 109, 112, 152
    - non-human primate model 110
- monocyte chemoattractant protein-1 (MCP-1) 186
- mouse model 109, 112, 152
- MSC, *see* mesenchymal stem cell
- multilineage differentiation 7
- multipotent adult progenitor cell (MAPC) 16, 35, 92, 142, 148 ff.
  - characterization 148
  - culture condition 148 ff.
  - cynomolgus monkey-derived (pMAPC) 149
  - differentiation potential 150 ff.
  - *ex-vivo* culture 153
  - mechanism 152 f.
  - phenotype 148
  - pluripotency 152
  - potential in animal model 147 ff.
  - proliferative capacity 148
- multipotent differentiation 147
- multipotent stem cell 210
- multipotentiality 28
- murine blastocyst 133 ff.
- murine embryo 141
- murine leukemia virus (MLV)-based retroviral vector 111
- murine neurosphere cell 142
- muscle
  - fiber 151
  - regeneration 180
  - smooth muscle 151
- myeloid cell 180
- myeloid-lymphoid initiating cell (ML-IC) 11
- myoblast 150, 207
- myocardial cell 81
  - therapy 209
- myocardial regeneration 197 ff.
- myocardium 189, 205 ff.
  - ischemic 189, 198
- myocyte 181
- myofibroblast 160 ff.
- myogenesis 205
- myogenic potential 216
- n**
- Nanog 148
- natural killer (NK) cell 151, 221 ff., 235
  - natural killer T (NK-T) cell 228

- neoangiogenesis 203  
 neovascularization 182  
 neural cell 80, 151  
 neural stem cell (NSC) 123 ff., 133 f.  
 neuroblast (NB) 12  
 neuroectoderm 152  
 neuron 150  
 neurosphere cell 134 ff.  
 2-(2-nitro-4-trifluoro-methylbenzoyl)-  
   1,3-cyclohexanedione 152  
 NOD-SCID 150  
 non-human primate model 110  
 non-obese diabetic (NOD) 150  
 nonhematopoietic cell 122, 234  
   – regenerative capacity 85  
 nonhematopoietic differentiation  
   potential 35  
 nonhematopoietic lineage 210  
 nonhematopoietic stem cell 85  
   – multipotent 85  
 notch family 34  
 NTBC, *see* 2-(2-nitro-4-trifluoro-methyl-  
   benzoyl)-1,3-cyclohexanedione  
 nuclear size 137 ff.
- o**
- oct3a 148  
 oct4 148  
 ontogeny 121, 157  
 Onyx-15 virus 168  
 osteoblast 150
- p**
- P-selectin 185  
 paracrine effect 183  
*pcna*, *see* proliferating cell nuclear antigen  
 PCR  
   – linear amplification-mediated  
     (LAM-PCR) 109  
 PEG-ADA, *see* polyethylene glycol  
   adenosine deaminase  
 percutaneous transluminal coronary  
   angioplasty (PTCA) 199  
 peripheral blood  
   – mobilized (mPB) 126  
 peripheral blood mononuclear cell  
   (PBMC) 180  
 peripheral blood progenitor cell (PBPC) 62  
   – mobilization 63  
 peripheral blood stem cell (PBSC) 239, 256  
 peripheral vascular disease 151  
 perivasculature cell 158  
   – human umbilical cord perivascular cell  
     (HUCPV) 85
- phytohemagglutinin (PHA) 235  
 plasmacytic lymphocyte 255  
 plasminogen-activator receptor  
   – urokinase-type (uPAR) 63  
 plasticity 9, 121  
 pluripotency 28, 143, 152  
 pluripotent embryonic state 143  
 pluripotent stem cell 73 ff., 180  
   – expansion 74  
   – generation 74  
 pMAPC, *see* multipotent adult progenitor cell,  
   cynomolgus monkey derived  
 polyethylene glycol adenosine deaminase  
   (PEG-ADA) 112  
 progenitor cell  
   – homing 181  
   – multipotent adult progenitor cell  
     (MAPC) 16, 35, 92, 142, 148 ff.  
   – therapy 190  
   – vascular progenitor 151  
   – vasculogenesis 184  
 proliferating cell nuclear antigen (*pcna*) 16  
 proliferation potential 147  
 prominin 179  
 protease  
   – matrix-degrading 162  
 proviral-genomic junction sequences 108  
 Purkinje fiber 81
- q**
- quality assurance 55, 99  
 quality control 99
- r**
- RANTES 186  
 reduced-intensity conditioning transplantation  
   (RICT) 249 ff.  
 regeneration 4 ff., 179 ff.  
   – cardiac 179 ff.  
   – myocardial 197 ff.  
   – tissue 157 ff.  
   – vascular 197 ff.  
 replacement therapy 18, 112, 128, 157  
 replicating oncoretroviral virus 168  
 retroviral integration site 113  
   – analysis 108  
 retroviral vector 111  
 Rex1 148  
 RNA  
   – micro RNA 43 ff.  
   – RNA-induced silencing complex  
     (RISC) 44 f.  
 RS phenotype 167

## S

- SB 290157 66
- SCID (severe compromised immunodeficient)
- ADA-SCID 110
  - mouse model 12, 164
  - SCID repopulating cell (SRC) 33
  - SCID-X1 111
- secretory leukocyte protease inhibitor (SLPI) 59
- self-renewal 147
- ability 7 ff.
- senescence 149
- side population 180
- simvastatin 60
- somatic cell 140
- sonic hedgehog 34
- sphingosine-1-phosphate 186
- stage-specific embryonic antigen (SSEA)-1 148
- stem cell 3 ff., 197 ff.
- acquisition 57
  - adult stem cell (ASC) 6 ff.
  - allogeneic stem cell transplantation (allo-SCT) 221, 234, 247 ff.
  - clinical potential 3 ff.
  - embryonic stem cell (ESC) 3 ff.
  - germline stem cell (GSC) 14
  - hematopoietic stem cell (HSC) 6 ff., 133 f.
  - human stem cell plasticity 121
  - homing 181
  - mesenchymal stem cell (MSC) 16 ff., 73 ff.
  - multipotent nonhematopoietic stem cell 85
  - multipotent stem cell 210
  - neural stem cell (NSC) 123, 133 f.
  - peripheral blood stem cell (PBSC) 239
  - pluripotent 73 ff., 180
  - preparation 55 ff.
  - regeneration 4 ff.
  - resource 73
  - somatic stem cell (SSC) 9, 133 ff.
  - therapy 190, 207
  - trans-differentiation 8
  - transplantation 247 ff.
  - unrestricted somatic stem cell (USSC) 16, 36, 73 ff.
  - vasculogenesis 184
- stemness 11 ff.
- stroma 157 ff.
- stromal cell-derived factor-1 (SDF-1) 58 ff., 186
- symmetric cell division 12, 28 ff.

## T

- T-cell 151, 252
- depletion (TCD) 252
  - T-cell inhibitory effector mechanism 238
- T-lymphocyte 235
- TAF, *see* tumor-associated fibroblast
- telomere 148
- teratocarcinoma 11
- therapeutic agent delivery 162 ff.
- therapeutic cloning 10
- Thy-1 11
- tissue
- engineering 163
  - regeneration 157
  - replacement therapy 128
- total body irradiation (TBI) 59
- total nuclear cell (TNC) 32
- totipotent 3
- toxicity 36
- trans-differentiation 6 ff., 142
- transcription factor 33
- transforming growth factor-beta (TGF- $\beta$ ) 158 ff.
- transgene expression 113 f.
- translational control
- miRNA-mediated 47
- transplantation 7, 163, 221 ff., 247 ff.
- allogeneic stem cell transplantation (allo-SCT) 221, 234, 247 ff.
  - bone marrow 7
  - fetal sheep 124
  - HLA-identical transplantation 228, 240, 251 ff.
  - *in-vivo* 123
  - reduced-intensity conditioning transplantation (RICT) 249 ff.
- transposon 46
- treatment-related mortality (TRM) 248
- trichostatin A (TSA) 29 ff.
- Trojan-Horse concept 158
- tryptophan depletion 238
- tumor 11
- development 161
  - genetic targeting 157
  - invasion 161
  - microenvironment 161
  - progression 158 ff.
  - stroma 161
  - tropism 162

- tumor-associated fibroblast (TAF) 158 ff.
  - tumor-associated macrophage 158
  - tumorigenesis 158
- u**
- umbilical cord blood 73 ff.
  - umbilical cord perivascular cell 85
    - human (HUCPV) 85
  - unpaired* 14
  - unrestricted somatic stem cell (USSC) 16, 36, 73 ff.
    - differentiation potential 77
    - expansion 74
    - generation 74
    - hepatic cell 81
    - immunophenotype 77
    - *in-vitro* differentiation 77
    - *in-vivo* differentiation 77
    - liver cell-specific differentiation 82
    - myocardial cell 81
    - Purkinje fiber 81
  - urokinase-type plasminogen-activator receptor (uPAR) 63
- v**
- valproic acid 33
  - vascular endothelial growth factor (VEGF) 158, 186
  - vascular progenitor 151
  - vascular regeneration 197 ff.
  - vascular remodelling 202 f.
  - vasculature cell 158
  - vasculogenesis 151, 184, 202 f.
  - very late antigen-4 (VLA-4) 57
  - virus 168
  - von Willebrand factor (vWF) 179
- w**
- Waldenström's disease 255
  - Waldenström's macroglobulinemia (WM) 255
  - wnt family 34
  - wound healing 158 ff.